AstraZeneca PLC (AZN.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca Pfc announces positive top-line results from the phase III programme of CAZ-AVI in patients with complicated Intra-Abdominal Infections (cIAI)


Tuesday, 19 Aug 2014 02:01am EDT 

AstraZeneca Pfc:Announces positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections.CAZ-AVI met the objective of statistical non-inferiority compared to meropenem.The primary endpoint was a clinical cure rate 28 to 35 days after randomisation (the Test of Cure visit).CAZ-AVI also treated cIAI patients infected with ceftazidime-resistant bacteria as effectively as meropenem.The adverse event rate for CAZ-AVI in combination with metronidazole was similar to meropenem. 

Company Quote

29.85
0.76 +2.61%
29 Jun 2016